Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of Clinical Oncology

• Publication date

  1992-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1200/JCO.1992.10.12.1897PMID 1453205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice

  2008cited by this paper
• Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice

  2004cited by this paper
• Fully automated determination of a new anthracycline N-l-leucyldoxorubicin and six metabolites in plasma by high-performance liquid chromatography with on-line sample handling.

  1992cited by this paper
• Human pharmacokinetics of N‐l‐leucyl‐doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities

  1992cited by this paper
• Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients.

  1991cited by this paper
• Pharmacodynamics in cancer therapy.

  1990cited by this paper
• Pharmacologically guided phase I clinical trials based upon preclinical drug development.

  1990cited by this paper
• Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

  1990cited by this paper
• Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites.

  1989cited by this paper
• Immunohistochemical and biochemical study of a cathepsin B-like proteinase in human colonic cancers.

  1988cited by this paper
• In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.

  1988cited by this paper
• Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

  1988cited by this paper
• Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

  1988cited by this paper
• Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.

  1987cited by this paper
• Potential roles for preclinical pharmacology in phase I clinical trials.

  1986cited by this paper
• Relation of preclinical toxicology to findings in early clinical trials.

  1986cited by this paper
• Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

  1985cited by this paper
• Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.

  1980cited by this paper
• Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion.

  1980cited by this paper
• Risk factors for doxorubicin-induced congestive heart failure.

  1979cited by this paper
• Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data

  1976cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper

• PRODRUG AND RECEPTOR MEDIATED DRUG TARGETING STRATEGIES OF PROSTATE CANCER

  2015cites this paper
• Protein- and Peptide-drug conjugates: an emerging drug delivery technology.

  2015cites this paper
• Monitoring subcellular biotransformation of N-l-leucyldoxorubicin by micellar electrokinetic capillary chromatography coupled to laser-induced fluorescence detection

  2014cites this paper
• Proteolytic profiling with imaging agents for rational design of target-activated peptide prodrugs

  2012cites this paper
• Lack ofin vitro interactions using human liver micro-somes between rabeprazole and anticancer drugs

  2010cites this paper
• Development of capillary electrophoretic-based techniques to analyze doxorubicin in tissues, cells and subcellular fractions.

  2010cites this paper
• Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques.

  2008cites this paper
• Novel peptidylaminoarylmethyl phosphoramide mustards for activation by prostate-specific antigen

  2008cites this paper
• Targeting - Cancer — Small Molecules

  2007cites this paper
• Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.

  2007cites this paper
• DNA-intercalators — the anthracyclines

  2006cites this paper
• Prodrugs of anthracyclines in cancer chemotherapy.

  2006cites this paper
• Advances in Brief Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen 1

  2006cites this paper
• Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells.

  2004cites this paper
• Analysis and pharmacokinetics ofN-l-leucyldoxorubicin and metabolites in tissues of tumor-bearing BALB/c mice

  2004cites this paper
• The identification of three human metabolites of a peptide-doxorubicin conjugate using HPLC-MS-MS in positive and negative ionization modes.

  2004cites this paper
• Drug-targeting strategies for prostate cancer.

  2003cites this paper
• CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

  2002cites this paper
• Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs

  2002cites this paper
• CPI-0004 Na , a New Extracellularly Tumor-Activated Prodrug of Doxorubicin : In Vivo Toxicity , Activity , and Tissue Distribution Confirm Tumor Cell Selectivity 1

  2002cites this paper
• Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.

  2001cites this paper
• Advances in Brief Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer : Application to Doxorubicin and Preliminary in Vitro and in Vivo Studies 1

  2001cites this paper
• Prodrug strategies in cancer therapy.

  2001cites this paper
• A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer

  2001cites this paper
• The role of pro-drug therapy in the treatment of cancer.

  2001cites this paper
• Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.

  2001cites this paper
• The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

  2001cites this paper
• In Vivo activity of a PSA‐activated doxorubicin prodrug against PSA‐producing human prostate cancer xenografts

  2000cites this paper
• Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug.

  1999cites this paper
• Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts.

  1999cites this paper
• Analysis of doxorubicin in cell culture media and human plasma using solid phase extraction and HPLC

  1999cites this paper
• Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?

  1999cites this paper
• The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

  1998cites this paper
• Human variability and noncancer risk assessment--an analysis of the default uncertainty factor.

  1998cites this paper
• Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.

  1998cites this paper
• Drug Development in Europe

  1997cites this paper
• Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.

  1996cites this paper
• Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.

  1996cites this paper
• Prodrugs of anticancer agents

  1996cites this paper
• Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

  1995cites this paper
• Dose optimization of anthracyclines.

  1994cites this paper
• Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

  1994cites this paper
• Anthracycline Antibiotics in Cancer Therapy

  1994cites this paper
• The role of biotransformation in anthracycline-induced cardiotoxicity in mice.

  1993cites this paper
• AD Award Number : DAMD 17-001-0028 TITLE : Enzymatic Activation of Proteasome Inhibitor Prodrugs by Prostate-Specific Antigen as Targeted Therapy for Prostate Cancer

  year unknowncites this paper